Cargando…

Erratum to: Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines

Detalles Bibliográficos
Autores principales:	Phillip, Cornel Joseph, Zaman, Shadia, Shentu, Shujun, Balakrishnan, Kumudha, Zhang, Jiexin, Baladandayuthapani, Veera, Taverna, Pietro, Redkar, Sanjeev, Wang, Michael, Stellrecht, Christine Marie, Gandhi, Varsha
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Erratum
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064904/ https://www.ncbi.nlm.nih.gov/pubmed/27737688 http://dx.doi.org/10.1186/s13045-016-0335-5

Ejemplares similares

Targeting MET kinase with the small-molecule inhibitor amuvatinib induces cytotoxicity in primary myeloma cells and cell lines
por: Phillip, Cornel Joseph, et al.
Publicado: (2013)

Targeting the Pro-Survival Protein MET with Tivantinib (ARQ 197) Inhibits Growth of Multiple Myeloma Cells()()
por: Zaman, Shadia, et al.
Publicado: (2015)

Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma
por: Baljevic, Muhamed, et al.
Publicado: (2017)

βIII‐tubulin suppression enhances the activity of Amuvatinib to inhibit cell proliferation in c‐Met positive non‐small cell lung cancer cells
por: Brayford, Simon, et al.
Publicado: (2022)

The Stromal Microenvironment Modulates Mitochondrial Oxidative Phosphorylation in Chronic Lymphocytic Leukemia Cells()()
por: Vangapandu, Hima V., et al.
Publicado: (2017)

A phase 2, open-label, multi-center study of amuvatinib in combination with platinum etoposide chemotherapy in platinum-refractory small cell lung cancer patients
por: Byers, Lauren Averett, et al.
Publicado: (2017)

ATP directed agent, 8-chloro-adenosine, induces AMP activated protein kinase activity, leading to autophagic cell death in breast cancer cells
por: Stellrecht, Christine M, et al.
Publicado: (2014)

Amuvatinib Blocks SARS-CoV-2 Infection at the Entry Step of the Viral Life Cycle
por: Huynh, Trang T. X., et al.
Publicado: (2023)

Bayesian Joint Selection of Genes and Pathways: Applications in Multiple Myeloma Genomics
por: Zhang, Lin, et al.
Publicado: (2014)

Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic
por: Balakrishnan, Kumudha, et al.
Publicado: (2016)

Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells
por: Modi, Prexy, et al.
Publicado: (2017)

Ataxia-telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma
por: Sarkar, Aloke, et al.
Publicado: (2020)

Reactive Oxygen Species (ROS) Inducible DNA Cross-Linking Agents and Their Effect on Cancer Cells and Normal Lymphocytes
por: Chen, Wenbing, et al.
Publicado: (2014)

Molecular evidence of Zn chelation of the procaspase activating compound B-PAC-1 in B cell lymphoma
por: Sarkar, Aloke, et al.
Publicado: (2015)

Regulation of Mcl-1 Expression in Context to Bone Marrow Stromal Microenvironment in Chronic Lymphocytic Leukemia()
por: Balakrishnan, Kumudha, et al.
Publicado: (2014)

PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells
por: Cervantes-Gomez, Fabiola, et al.
Publicado: (2019)

c-Met signaling promotes IL-6-induced myeloma cell proliferation
por: Hov, Håkon, et al.
Publicado: (2009)

Geldanamycin and Its Derivatives Inhibit the Growth of Myeloma Cells and Reduce the Expression of the MET Receptor
por: Jurczyszyn, Artur, et al.
Publicado: (2014)

The Amuvatinib Derivative, N-(2H-1,3-Benzodioxol-5-yl)-4-{thieno[3,2-d]pyrimidin-4-yl}piperazine-1-carboxamide, Inhibits Mitochondria and Kills Tumor Cells under Glucose Starvation
por: Marciano, Ran, et al.
Publicado: (2020)

Vecabrutinib inhibits B-cell receptor signal transduction in chronic lymphocytic leukemia cell types with wild-type or mutant Bruton tyrosine kinase
por: Aslan, Burcu, et al.
Publicado: (2021)

Targeting Oxidative Stress With Auranofin or Prima-1(Met) to Circumvent p53 or Bax/Bak Deficiency in Myeloma Cells
por: Tessoulin, Benoit, et al.
Publicado: (2019)

GTN057, a komaroviquinone derivative, induced myeloma cells' death in vivo and inhibited c‐MET tyrosine kinase
por: Okayama, Mikio, et al.
Publicado: (2023)

Extramedullary manifestations of multiple myeloma in the thyroid gland and in the lungs: excellent response to therapy
por: Weisser, Fabia, et al.
Publicado: (2010)

Insights into Host Cell Modulation and Induction of New Cells by the Corn Smut Ustilago maydis
por: Redkar, Amey, et al.
Publicado: (2017)

Tyrosine kinase signaling-independent MET-targeting with CAR-T cells
por: Qin, Anna, et al.
Publicado: (2023)

Involvement of multiple myeloma cell-derived exosomes in osteoclast differentiation
por: Raimondi, Lavinia, et al.
Publicado: (2015)

A phase I-II trial of fludarabine, bendamustine and rituximab (FBR) in previously treated patients with CLL
por: Jain, Nitin, et al.
Publicado: (2016)

MET Inhibitor Capmatinib Radiosensitizes MET Exon 14-Mutated and MET-Amplified Non-Small Cell Lung Cancer
por: Ramesh, Shrey, et al.
Publicado: (2023)

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
por: Kim, Seulki, et al.
Publicado: (2019)

Endothelial progenitor cells display clonal restriction in multiple myeloma
por: Braunstein, Marc, et al.
Publicado: (2006)

MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis
por: Liang, Hongge, et al.
Publicado: (2020)

MET and Small-Cell Lung Cancer
por: Gelsomino, Francesco, et al.
Publicado: (2014)

Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells
por: Petti, Consalvo, et al.
Publicado: (2014)

Meeting an un-MET need: Targeting MET in non-small cell lung cancer
por: Michaels, Elena, et al.
Publicado: (2022)

Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody
por: Kou, Jianqun, et al.
Publicado: (2018)

MET Inhibition in Clear Cell Renal Cell Carcinoma
por: Xie, Zuoquan, et al.
Publicado: (2016)

Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
por: Park, Chi Hoon, et al.
Publicado: (2016)

Chimeric Antigen Receptor T Cell Therapy and Its Significance in Multiple Myeloma
por: Padda, Jaskamal, et al.
Publicado: (2021)

MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells
por: Presutti, Dario, et al.
Publicado: (2015)

When microarrays Met epidermal-cell migration
por: Janes, Kevin A
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_qp88t5p4802nqq5kd86mr8lf8o